Lipocine (LPCN) stock price, revenue, and financials

Lipocine market cap is $101.2 m, and annual revenue was $164.99 k in FY 2019
View Company

$101.2 M

LPCN Mkt cap, 08-Jan-2021
Lipocine Net income (Q2, 2020)-6.4 M
Lipocine EBIT (Q2, 2020)-4.2 M
Lipocine Cash, 30-Jun-202013.8 M
Lipocine EV93.7 M

Lipocine Income Statement

Annual

USDFY, 2012Y, 2013FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

428.0k165.0k

R&D expense

5.1m15.5m12.6m8.1m11.0m6.5m7.5m

General and administrative expense

76.7k3.6m5.0m5.8m10.4m10.2m5.3m5.6m

Operating expense total

76.7k8.8m20.6m18.6m19.2m21.2m11.8m13.1m

EBIT

(76.7k)(10.7m)(10.7m)(20.5m)(18.4m)(19.2m)(21.2m)(11.3m)(12.9m)

EBIT margin, %

(2646%)(7819%)

Pre tax profit

(10.6m)(20.4m)(18.2m)(19.0m)(21.0m)(11.7m)(13.0m)

Income tax expense

55.0k(55.0k)200.0200.0752.0700.0700.0200.0

Net Income

(76.7k)(10.6m)(10.6m)(20.4m)(18.2m)(19.0m)(21.0m)(11.7m)(13.0m)

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

428.0k165.0k

R&D expense

1.6m3.4m6.0m3.2m1.9m3.2m4.7m2.7m2.6m1.5m3.1m4.1m2.0m1.4m1.5m1.4m1.9m2.0m1.7m2.5m2.3m

General and administrative expense

2.2k3.3k5.7k3.2k6.3k1.2m1.9m1.0m871.8k1.1m1.1m1.7m4.4m3.2m1.4m1.8m2.0m2.7m1.7m1.7m930.1k1.2m1.4m1.4m2.1m2.0m

Operating expense total

2.2k3.3k5.7k3.2k6.3k2.8m5.3m7.0m4.1m3.0m4.3m6.5m7.1m5.9m3.3m5.0m6.2m4.8m3.1m3.2m2.4m3.1m3.4m3.1m4.6m4.2m

EBIT

(4.8k)(5.7k)(3.2k)(6.3k)(3.5m)(5.3m)(7.0m)(4.1m)(3.0m)(4.3m)(6.4m)(7.1m)(5.8m)(3.3m)(4.9m)(6.1m)(4.8m)(2.6m)(3.2m)(2.4m)(3.1m)(3.4m)(3.0m)(4.6m)(4.2m)

EBIT margin, %

(616%)(1804%)

Interest expense

82.3k91.1k106.0k

Interest income

110.2k120.4k112.6k125.3k124.6k99.0k59.9k7.2k

Pre tax profit

(3.5m)(5.3m)(7.0m)(4.1m)(3.0m)(4.2m)(6.4m)(7.0m)(5.8m)(3.2m)(4.9m)(6.1m)(4.7m)(2.7m)(3.3m)(2.5m)(3.2m)(3.4m)(3.1m)(5.8m)(6.4m)

Income tax expense

(55.3k)200.0700.0700.0700.0700.0200.0

Net Income

(4.8k)(61.2k)(5.7k)(3.2k)(6.3k)(3.5m)(5.3m)(7.0m)(4.1m)(3.0m)(4.2m)(6.4m)(7.0m)(5.8m)(3.2m)(4.9m)(6.1m)(4.7m)(2.7m)(3.3m)(2.5m)(3.2m)(3.4m)(3.1m)(5.8m)(6.4m)

Lipocine Balance Sheet

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

577.045.3m27.7m20.0m5.6m3.2m8.1m9.7m

Accounts Receivable

Prepaid Expenses

770.0k229.9k350.2k408.2k520.1k545.9k

Inventories

Current Assets

577.046.0m27.9m44.9m27.2m25.2m20.8m19.6m

PP&E

28.8k73.8k75.8k75.1k19.0k3.6k

Total Assets

577.046.1m28.0m45.4m27.3m25.3m20.9m19.7m

Accounts Payable

11.7k1.0m306.3k507.1k245.9k598.1k671.3k1.2m

Short-term debt

3.3m3.3m

Current Liabilities

11.9k1.3m1.6m3.4m1.3m6.3m4.5m5.0m

Long-term debt

16.9m3.8m

Total Debt

20.3m7.1m

Total Liabilities

1.3m1.6m3.4m1.3m6.3m11.4m13.4m

Common Stock

350.01.3k1.3k1.8k2.1k2.2k3.8k

Preferred Stock

Additional Paid-in Capital

70.2k92.7m94.6m128.5m131.5m145.4m147.5m157.4m

Retained Earnings

(47.9m)(68.2m)(86.4m)(105.4m)(126.4m)(138.1m)(151.1m)

Total Equity

(11.3k)44.8m26.4m42.0m26.0m19.0m9.4m6.3m

Debt to Equity Ratio

2.1 x

Debt to Assets Ratio

1 x

Financial Leverage

-0.1 x1 x1.1 x1.1 x1.1 x1.3 x2.2 x3.1 x

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

17.9k3.4k622.0458.010.036.8m41.8m34.2m31.7m24.8m38.3m23.9m14.1m12.4m4.7m6.9m16.6m9.3m8.6m1.6m4.8m8.2m3.7m6.7m15.1m13.8m

Prepaid Expenses

251.7k256.4k1.3m285.9k186.5k181.3k347.8k268.9k154.0k457.4k262.0k88.6k453.4k248.0k113.3k728.5k411.4k148.9k754.5k373.4k147.3k

Current Assets

622.0458.010.037.1m42.0m35.4m32.0m25.0m44.1m42.3m38.6m33.2m29.4m27.1m27.9m26.1m31.6m25.3m22.6m23.0m19.6m17.3m21.0m23.5m

PP&E

34.8k27.6k24.6k40.7k82.7k79.9k82.9k108.3k119.9k111.7k96.3k89.3k82.2k32.3k27.9k23.4k15.1k11.3k7.4k2.8k2.0k

Total Assets

622.0458.010.037.2m42.1m35.5m32.0m25.1m53.8m48.4m38.8m33.3m29.6m27.2m28.0m26.3m31.7m25.3m22.7m23.0m19.7m17.3m21.0m23.5m

Accounts Payable

6.8k14.8k17.4k1.5m773.0k641.8k399.1k379.5k398.8k456.8k1.1m989.0k865.0k853.5k1.1m803.8k388.4k406.5k239.9k517.7k116.0k1.4m1.7m906.8k

Short-term debt

1.3m1.5m2.3m3.3m3.3m3.3m1.7m2.3m

Current Liabilities

7.0k15.0k17.6k1.6m1.5m1.7m2.1m1.3m1.7m2.2m3.0m2.6m1.6m2.3m2.9m2.5m6.3m2.8m3.1m4.3m4.4m5.2m4.1m4.2m

Long-term debt

18.7m18.6m7.9m6.2m5.4m4.6m4.7m4.0m

Total Debt

20.1m20.1m10.2m9.5m8.7m7.9m6.4m6.3m

Total Liabilities

1.6m1.5m1.7m2.1m1.3m1.7m2.2m3.0m2.6m1.6m2.3m2.9m2.5m15.0m11.4m10.9m10.4m9.8m9.8m14.4m10.4m

Common Stock

350.0350.0350.01.1k1.3k1.3k1.3k1.3k1.8k1.8k1.8k1.8k1.8k1.9k2.1k2.1k2.1k2.1k2.1k2.5k2.5k2.5k4.8k6.1k

Preferred Stock

Additional Paid-in Capital

70.2k70.2k70.2k79.0m93.7m94.0m94.2m95.0m127.6m128.1m129.3m130.0m130.5m135.2m141.6m144.9m145.9m146.3m146.6m153.9m154.6m155.3m163.4m176.3m

Retained Earnings

(43.5m)(53.1m)(60.1m)(64.2m)(71.2m)(75.4m)(81.8m)(93.5m)(99.2m)(102.5m)(110.3m)(116.4m)(121.1m)(129.1m)(132.4m)(134.8m)(141.3m)(144.7m)(147.8m)(156.8m)(163.2m)

Total Equity

(6.4k)(14.5k)(17.6k)35.5m40.6m33.8m30.0m23.7m52.1m46.2m35.8m30.8m28.0m24.9m25.1m23.8m16.7m13.9m11.8m12.6m9.9m7.5m6.6m13.1m

Debt to Equity Ratio

1.2 x1.5 x0.9 x0.8 x0.9 x

Debt to Assets Ratio

0.6 x0.8 x0.4 x0.4 x0.4 x

Financial Leverage

-0.1 x0 x0 x1 x1 x1 x1.1 x1.1 x1 x1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.9 x1.8 x1.9 x1.8 x2 x2.3 x3.2 x1.8 x

Lipocine Cash Flow

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(76.7k)(10.6m)(20.4m)(18.2m)(19.0m)(21.0m)(11.7m)(13.0m)

Depreciation and Amortization

21.8k14.6k26.7k32.0k28.4k18.6k15.4k

Accounts Receivable

Accounts Payable

4.3k668.8k(449.6k)200.8k(261.2k)352.2k73.2k511.0k

Cash From Operating Activities

(62.9k)(8.6m)(17.3m)(15.4m)(18.3m)(16.7m)(12.1m)(11.7m)

Purchases of PP&E

(1.2k)(59.6k)(28.7k)(59.6k)

Cash From Investing Activities

(1.2k)(38.4k)(25.0m)3.2m3.1m11.3m3.0m

Long-term Borrowings

(3.3m)

Cash From Financing Activities

40.5k48.5m(255.1k)32.7m605.9k11.2m10.7m10.3m

Net Change in Cash

(22.4k)39.9m(17.6m)(7.7m)(14.4m)(2.3m)9.9m1.7m

Interest Paid

533.5k545.5k

Income Taxes Paid

(55.0k)700.0700.0700.0

Quarterly

USDQ1, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(4.8k)(71.7k)(3.2k)(6.3k)(6.2m)(5.3m)(12.2m)(16.3m)(3.0m)(7.2m)(13.6m)(7.0m)(12.8m)(16.0m)(4.9m)(11.0m)(15.7m)(2.7m)(6.0m)(8.4m)(3.2m)(6.7m)(9.7m)(5.8m)(12.1m)

Depreciation and Amortization

15.7k3.0k6.1k9.4k4.3k8.7k19.6k6.7k15.5k23.7k7.1k14.2k21.3k5.3k9.7k14.2k3.9k7.7k11.6k799.01.6k

Accounts Receivable

Accounts Payable

(612.0)3.1k5.7k1.1m(254.0k)(385.2k)(627.9k)73.3k30.1k150.6k570.1k482.0k357.9k607.6k867.9k557.9k(209.7k)(191.5k)(358.1k)(153.6k)(555.2k)689.2k472.7k(275.4k)

Cash From Operating Activities

(5.1k)(62.8k)(119.0)(567.0)(4.5m)(3.5m)(11.1m)(13.6m)(3.0m)(6.9m)(12.4m)(6.5m)(11.7m)(15.7m)(3.1m)(7.8m)(12.4m)(3.7m)(6.5m)(9.8m)(3.0m)(5.6m)(8.4m)(3.4m)(7.5m)

Purchases of PP&E

(1.2k)(1.9k)(1.9k)(21.3k)(13.2k)(14.8k)(28.7k)(39.2k)(59.6k)(59.6k)

Cash From Investing Activities

(1.2k)(1.9k)19.4k(33.0)(13.2k)(15.1m)(24.0m)582.1k4.0m399.6k1.4m10.1m4.9m(903.2k)(122.3k)6.3m(2.1m)(3.5m)2.4m3.9m(116.8k)

Long-term Borrowings

(833.3k)(1.7m)(2.5m)(833.3k)(1.1m)

Cash From Financing Activities

40.5k35.9m16.1k16.1k136.9k32.7m32.7m34.2k34.2k34.2k3.1m8.8m11.2m10.0m10.0m10.1m5.2m4.7m4.5m4.9m11.7m

Net Change in Cash

(22.3k)(119.0)(567.0)31.5m(3.5m)(11.1m)(13.6m)(2.9m)10.6m(3.7m)(5.9m)(7.6m)(15.3m)1.4m11.1m3.7m5.4m3.4m6.6m144.6k(4.4m)(1.4m)5.4m4.1m

Interest Paid

274.0k427.6k156.8k304.5k436.6k93.0k157.0k

Income Taxes Paid

700.0700.0700.0700.0700.0700.0700.0700.0700.0700.0700.0200.0

Lipocine Ratios

USDQ1, 2012
View Lipocine profile

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Learn more